Engineering therapeutic antibodies targeting G-protein–coupled receptors.
- Author:
Migyeong JO
1
;
Sang Taek JUNG
Author Information
- Publication Type:Review
- MeSH: Animals, Laboratory; Antibodies*; Epitopes; Immunization; Inflammation; Mass Screening
- From:Experimental & Molecular Medicine 2016;48(2):e207-
- CountryRepublic of Korea
- Language:English
- Abstract: G-protein–coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.
